List of Excipients in Branded Drug FLO-PRED

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Taro Pharmaceuticals USA Inc	FLO-PRED	prednisolone acetate	51672-1338	BUTYLPARABEN
Taro Pharmaceuticals USA Inc	FLO-PRED	prednisolone acetate	51672-1338	CARBOMER HOMOPOLYMER TYPE B
Taro Pharmaceuticals USA Inc	FLO-PRED	prednisolone acetate	51672-1338	EDETATE DISODIUM
Taro Pharmaceuticals USA Inc	FLO-PRED	prednisolone acetate	51672-1338	GLYCERIN

FLO-PRED Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

FLO-PRED is an oral prednisolone acetate suspension containing 15 mg/5 mL. Its commercial differentiation depends less on the active ingredient, which is long established, than on suspension stability, dose uniformity, palatability, preservative selection, and reliable pediatric administration. The main opportunities are an authorized generic, a therapeutically equivalent ANDA product, preservative-free or unit-dose reformulation, and differentiated pediatric packaging.

FLO-PRED does not present a biosimilar opportunity because prednisolone acetate is a small-molecule corticosteroid. Market entry is governed by the abbreviated new drug application pathway, formulation performance, labeling requirements, and any current Orange Book listings rather than by the biosimilar pathway.

What is FLO-PRED and which formulation does it use?

FLO-PRED is a prescription oral suspension of prednisolone acetate, a glucocorticoid used for corticosteroid-responsive conditions. The labeled strength is 15 mg/5 mL, equivalent to 3 mg/mL [1].

Prednisolone acetate has limited aqueous solubility. FLO-PRED therefore uses a suspension rather than a clear solution. The formulation must maintain a uniform distribution of suspended drug during storage and after shaking by the patient or caregiver.

Product attribute	FLO-PRED profile
Active ingredient	Prednisolone acetate
Dosage form	Oral suspension
Labeled strength	15 mg/5 mL
Concentration	3 mg/mL
Therapeutic class	Systemic corticosteroid
Primary users	Adults and pediatric patients requiring oral corticosteroid therapy
Regulatory pathway for competitors	ANDA for a therapeutically equivalent product
Biosimilar pathway	Not applicable
Key technical issue	Suspension uniformity and dose reproducibility

The formulation is commercially relevant because an oral suspension can serve patients who cannot swallow tablets, including young children and patients with dysphagia. The same dosage form creates manufacturing risks involving sedimentation, redispersion, viscosity, container compatibility, and dose measurement.

Which excipients are used in FLO-PRED?

The FDA labeling identifies the following inactive ingredients: citric acid, edetate disodium, flavor, polysorbate 80, sodium benzoate, sodium citrate, sucrose, and purified water [1].

Excipient	Likely formulation function	Commercial and regulatory relevance
Citric acid	Acidulant and pH adjustment	Supports pH control and may affect preservative performance
Sodium citrate	Buffer component	Controls pH and helps reduce batch-to-batch variability
Edetate disodium	Chelating agent	Binds trace metals that can promote degradation or reduce preservative performance
Polysorbate 80	Wetting and dispersing agent	Improves wetting of hydrophobic prednisolone acetate particles
Sodium benzoate	Antimicrobial preservative	Supports multidose container use but creates preservative-sensitivity and labeling considerations
Sucrose	Sweetener and mouthfeel modifier	Improves pediatric acceptability; introduces sugar-related positioning limits
Flavor	Taste masking	Important for adherence and caregiver acceptance
Purified water	Vehicle	Defines the aqueous suspension system

The excipient system is conventional, but its value lies in the interaction among components. Polysorbate 80 must wet prednisolone acetate particles without creating excessive foaming or destabilizing the suspension. The citrate buffer must support chemical stability while preserving sodium benzoate activity. Edetate disodium can improve preservative robustness by reducing the impact of trace-metal contamination.

Sucrose and flavor are central to pediatric use. They also create opportunities for alternative products marketed around reduced sugar, sugar-free dosing, or improved taste. Those claims would require appropriate comparative taste, stability, and labeling support.

How does the FLO-PRED excipient system support suspension performance?

The formulation has four technical objectives:

1. Keep prednisolone acetate uniformly dispersed.
2. Allow rapid redispersion after settling.
3. Maintain dose accuracy throughout the labeled shelf life.
4. Provide acceptable taste and microbial control.

A generic manufacturer cannot assume that matching the ingredient list will produce therapeutic equivalence. The critical quality attributes include particle-size distribution, polymorphic form, sedimentation behavior, redispersibility, viscosity, pH, assay, degradation products, microbial limits, preservative effectiveness, and delivered dose.

The most important development variable is likely the physical form of prednisolone acetate. Smaller particles can improve uniformity but may increase agglomeration, viscosity, or manufacturing complexity. Larger particles can settle rapidly and create dose nonuniformity. A controlled particle-size distribution, combined with effective wetting, is more commercially defensible than a simple excipient substitution.

Container closure also matters. A multidose bottle must preserve suspension quality while limiting microbial ingress. Bottle geometry, neck design, cap liner, dosing syringe, and shake instructions affect actual delivered dose. An oral syringe can reduce measurement variability compared with a household teaspoon and provides a packaging-based differentiation opportunity.

What formulation patents could protect FLO-PRED or competing products?

The active ingredient is old and generally offers limited composition-of-matter protection. Commercial protection would more likely arise from formulation, manufacturing, packaging, or method-of-use claims.

Potential claim categories include:

• An aqueous prednisolone acetate suspension with defined particle-size limits.
• A specific ratio of polysorbate 80, citrate buffer, chelator, preservative, and sweetener.
• Improved redispersibility after defined storage conditions.
• A formulation with specified pH, viscosity, sedimentation volume, or particle-size distribution.
• A preservative-free or reduced-preservative suspension with validated microbial control.
• A unit-dose container or prefilled oral dosing device.
• A manufacturing process that controls wetting, homogenization, milling, or particle-size distribution.
• Taste-masking systems with defined flavor or sweetener combinations.

The strongest patent strategy would require claims tied to measurable performance, such as dose uniformity after storage, rapid redispersion, chemical stability, or improved palatability. Broad claims covering prednisolone acetate plus common excipients would face greater prior-art and obviousness risk.

An applicant seeking to market a generic FLO-PRED-equivalent product would need to review the current FDA Orange Book patent and exclusivity records for the relevant NDA. Public labeling alone does not establish the full patent position. The Orange Book is the controlling source for listed patents and use codes [2].

When did FLO-PRED lose exclusivity?

FLO-PRED was approved under NDA 022051 in 2008 [1]. Prednisolone acetate was not a new molecular entity at the time of approval. Any regulatory exclusivity associated with new clinical investigations would have been time-limited and would not normally remain a current barrier more than a decade later.

The commercial entry question is therefore primarily a patent and ANDA issue. A competing applicant would need to assess:

• Current Orange Book patent listings for NDA 022051.
• Whether any listed patent has expired, been delisted, or remains enforceable.
• Whether the listed patents contain formulation claims, method-of-use claims, or both.
• Whether a Paragraph IV certification is required.
• Whether the reference product has a recognized therapeutic-equivalence code.
• Whether the product is currently marketed in a manner that supports ANDA reference-product selection.

A Paragraph IV certification would assert that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic. The NDA holder could file patent litigation within 45 days, triggering a statutory stay of FDA approval for up to 30 months under the Hatch-Waxman framework, subject to statutory exceptions [3].

What is the Orange Book status of FLO-PRED?

The relevant FDA regulatory record is NDA 022051. The Orange Book should be reviewed for:

Review item	Business significance
Reference listed drug designation	Determines the product used for ANDA comparison
Therapeutic-equivalence code	Indicates FDA’s equivalence determination
Listed patents	Defines potential Paragraph IV and certification requirements
Patent use codes	Limits the scope of method-of-use protection
Marketing status	Indicates whether the reference product is currently marketed
Discontinued status	Can affect sourcing and regulatory strategy

The marketing position of the brand has commercial importance. Akorn, historically associated with FLO-PRED, entered bankruptcy proceedings and ceased broad operations in 2023. Any acquirer or generic developer should separate three questions: whether the NDA remains active, whether the reference product is currently marketed, and whether a reliable commercial supply of reference product exists. Those issues affect development timing, product sourcing, and launch execution.

What generic entry opportunities exist for FLO-PRED?

The most direct opportunity is a 15 mg/5 mL prednisolone acetate oral suspension submitted through an ANDA. A successful product would compete on availability, wholesaler access, pricing, and pediatric usability.

Authorized generic opportunity

An authorized generic could preserve the existing formulation and label while reducing brand erosion risk. Its advantages include shorter commercial development, familiar packaging, and potential use of existing manufacturing knowledge. Its weakness is limited differentiation and likely price compression.

Independent ANDA opportunity

An independent ANDA could compete through:

• Lower acquisition cost.
• More reliable supply.
• Unit-dose packaging.
• An oral syringe included in every package.
• Improved flavor.
• Smaller bottle sizes for pediatric use.
• A preservative-free presentation, if technically and commercially justified.
• Sugar-free positioning.

Reformulation opportunity

A reformulated product could target patients or caregivers who object to sucrose, sodium benzoate, or certain flavors. A sugar-free product could use alternative sweeteners, but those ingredients may create new taste, gastrointestinal, or stability issues. A preservative-free multidose suspension would face a higher microbiological-control burden and may require specialized packaging, aseptic filling, or a validated in-use stability period.

Institutional opportunity

Hospitals, pediatric clinics, specialty pharmacies, and long-term-care facilities may value unit-dose presentations and standardized oral syringes. These formats can reduce medication errors and simplify administration, although the packaging cost may exceed that of a conventional bottle.

How strong is the FLO-PRED patent estate?

The likely patent strength is moderate to weak at the active-ingredient level and potentially stronger at the formulation level.

Protection layer	Expected strength
Prednisolone acetate composition of matter	Weak because the molecule is long established
Broad oral corticosteroid claims	Weak
Specific suspension composition	Potentially moderate, depending on claim scope and prior art
Particle-size and redispersibility claims	Potentially moderate to strong if supported by comparative data
Preservative or buffer combination	Usually vulnerable if based on routine formulation selection
Packaging and dosing device	Potentially protectable but commercially narrow
Method-of-use claims	Dependent on listed use codes and patent status
Manufacturing process	Stronger when process parameters produce non-obvious product attributes

A competitor should expect the principal legal risk to involve formulation patents rather than molecular patents. Freedom-to-operate analysis should cover U.S. patents and applications, continuations, foreign counterparts, and assignment history. It should also address excipient supplier agreements and any proprietary prednisolone acetate particle-engineering process.

What FDA and manufacturing barriers affect a FLO-PRED generic?

FDA review will focus on pharmaceutical equivalence, bioequivalence, product quality, and labeling. For a suspension, the development package must demonstrate control of attributes that can change drug exposure or dose delivery. The applicant should prioritize:

• Comparative assay and content uniformity.
• Particle-size distribution.
• Sedimentation and redispersion testing.
• Shake-time robustness.
• Viscosity and syringeability.
• Preservative effectiveness.
• Microbial limits.
• Extractables and leachables.
• In-use stability after opening.
• Container-closure integrity.
• Delivered-volume accuracy.

Manufacturing barriers include reproducible wetting of the active ingredient, prevention of agglomeration, control of foam, and consistent suspension filling. A product can meet assay specifications while still failing commercially if it settles into a hard cake or delivers inconsistent doses.

FDA’s Inactive Ingredient Database can support excipient selection, but prior use of an excipient in an approved product does not eliminate the need to justify concentration, route, dosage form, and patient exposure [4].

How does FLO-PRED compare with competing prednisolone products?

FLO-PRED competes with prednisolone sodium phosphate solutions, prednisolone tablets, orally disintegrating products, and compounded oral suspensions.

Product type	Main advantage	Main limitation
Prednisolone acetate suspension	Established 15 mg/5 mL suspension format	Requires shaking and has settling risk
Prednisolone sodium phosphate solution	Clear solution with no sedimentation	Different active ingredient and excipient profile
Tablets	Low manufacturing and packaging cost	Poor fit for young children and dysphagic patients
Compounded suspension	Flexible strength and flavor	Variable availability, quality, and reimbursement
Unit-dose suspension	Dose-control and institutional convenience	Higher packaging cost

A sodium phosphate solution is the most important technical comparator because it avoids suspension instability. A new prednisolone acetate product must justify why its dosage form remains attractive, typically through dose flexibility, established prescribing familiarity, or a better pediatric administration profile.

What revenue exposure and commercial metrics matter?

Public FDA records do not report FLO-PRED net sales. The commercial assessment should instead use prescription volume, payer claims, wholesaler data, product availability, and the size of the broader oral prednisolone market.

The most relevant metrics are:

• Annual U.S. prescriptions for prednisolone oral liquids.
• Share of prescriptions using prednisolone acetate rather than prednisolone sodium phosphate.
• Average selling price and generic discount.
• Pediatric versus adult utilization.
• Cash-pay and Medicaid concentration.
• Shortage history and pharmacy substitution behavior.
• Hospital and specialty-pharmacy purchasing.
• Bottle-size and dosing-device preferences.

The opportunity is more likely to be a niche, high-utility liquid product than a large pharmaceutical franchise. Margin improvement would depend on manufacturing scale, supply reliability, packaging efficiency, and differentiation that prevents immediate commoditization.

Key Takeaways

• FLO-PRED is a 15 mg/5 mL prednisolone acetate oral suspension.
• Its excipient strategy combines wetting, buffering, chelation, preservation, sweetening, flavoring, and aqueous vehicle functions.
• The main technical risks are sedimentation, redispersion, dose uniformity, microbial control, and taste.
• Molecular patent protection is unlikely to be the central barrier; formulation, process, and packaging claims are more relevant.
• Generic entry would normally proceed through an ANDA, with Paragraph IV analysis based on current Orange Book records.
• There is no biosimilar pathway for FLO-PRED.
• Commercial opportunities include an authorized generic, an independent ANDA, preservative-free or sugar-free reformulation, and unit-dose pediatric packaging.
• The strongest product differentiation would be measurable improvement in dose delivery, palatability, in-use stability, or packaging usability.

FAQs About FLO-PRED Excipient and Commercial Strategy

Can FLO-PRED be reformulated as a clear oral solution?

Not without changing the active pharmaceutical ingredient or using a solubilization approach that materially alters the product. Prednisolone acetate’s low aqueous solubility is the principal reason the product is formulated as a suspension.

Would a sugar-free FLO-PRED generic have a regulatory advantage?

It could have commercial value for selected patients, but it would not automatically receive regulatory exclusivity. The product would still need to demonstrate pharmaceutical quality, stability, palatability, and therapeutic equivalence where applicable.

Is sodium benzoate essential to the FLO-PRED formulation?

No. It is the labeled preservative, but a competing product could use another validated preservation strategy. The alternative would require appropriate microbiological and stability support.

Can a compounder create a substitute for FLO-PRED?

Compounding pharmacies may prepare prednisolone suspensions under applicable federal and state requirements. Compounded products do not automatically have the same FDA approval, manufacturing controls, labeling, or equivalence status as an approved generic.

What is the most defensible commercial differentiator for a FLO-PRED competitor?

A product combining validated suspension performance with an oral syringe, improved taste, reliable supply, and a practical pediatric package is likely more defensible than a minor excipient substitution alone.

References

1. U.S. Food and Drug Administration. (2008). FLO-PRED (prednisolone acetate) oral suspension prescribing information. NDA 022051.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2015). Guidance for industry: 180-day exclusivity when multiple ANDAs are submitted on the same day.
4. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database.